HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Gabapentin in the treatment of chronic intractable pain].

AbstractINTRODUCTION:
Gabapentin has been shown to reduce pain associated with diabetic neuropathia and postherpetic neuralgia. To date it is not known, whether gabapentin is generally effective in other types of pain. It was therefore the aim to study gabapentin in patients suffering from intractable pain with respect to efficacy, predictive factors and side effects.
METHODS:
Retrospective analysis of the data sheet of pretreated patients suffering from intractable pain and treated with gabapentin as a third line drug at a university pain clinic. Pain intensity (visual analogue scale, VAS 0 -10 cm), pain characteristics, diagnosis, pre- and co-treatment, and side effects were assessed. Response to treatment was defined as a 50% reduction in pain or a pain intensity of VAS </= 3.
RESULTS:
99 patients were included. Approximately half the patients (n = 49) responded to gabapentin. Patients suffering from neuropathic pain showed a higher response rate (60%) compared to patients with muscle-sceletal pain (35%). Allodynia was twice as high in the responders (35%) compared to the non-responders (18%) before treatment. No serious side effects were reported.
CONCLUSION:
Gabapentin was effective in approximately 50% of pretreated patients with intractable pain. Neuropathic pain responded better than pain of other origine. Allodynia may be a predictive factor for a positive treatment effect.
AuthorsB Gustorff, G Nahlik, A Spacek, H G Kress
JournalSchmerz (Berlin, Germany) (Schmerz) Vol. 16 Issue 1 Pg. 9-14 (Feb 2002) ISSN: 0932-433X [Print] Germany
Vernacular TitleGabapentin in der Therapie chronischer therapieresistenter Schmerzen. Erste Erfahrungen bei 99 Patienten.
PMID11845336 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Acetates
  • Amines
  • Analgesics
  • Analgesics, Non-Narcotic
  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclohexanecarboxylic Acids
  • Placebos
  • Serotonin Uptake Inhibitors
  • Triazines
  • Amitriptyline
  • Carbamazepine
  • gamma-Aminobutyric Acid
  • Gabapentin
  • Lamotrigine
Topics
  • Acetates (administration & dosage, adverse effects, therapeutic use)
  • Amines
  • Amitriptyline (administration & dosage, therapeutic use)
  • Analgesics (administration & dosage, adverse effects, therapeutic use)
  • Analgesics, Non-Narcotic (administration & dosage, therapeutic use)
  • Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, therapeutic use)
  • Carbamazepine (administration & dosage, therapeutic use)
  • Chronic Disease
  • Cyclohexanecarboxylic Acids
  • Drug Therapy, Combination
  • Gabapentin
  • Humans
  • Lamotrigine
  • Pain, Intractable (diagnosis, drug therapy)
  • Placebos
  • Retrospective Studies
  • Selective Serotonin Reuptake Inhibitors (administration & dosage, therapeutic use)
  • Time Factors
  • Triazines (administration & dosage, therapeutic use)
  • gamma-Aminobutyric Acid

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: